From: Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
Treatment line | Start and stop, year/month | Sites of metastasis | Therapeutic schedule | Best response | TTP (months) |
---|---|---|---|---|---|
1st | 1996/ to 1997/3 | Lung | Paclitaxel 80 mg/m2 weekly (day 1–8–15, w4) | PR | 12 |
2nd | 1997/4 to 2000/1 | Lung | Megestrol 160 mg dailya | PR | 33 |
3rd | 2000/1 to 2001/1 | Lung | Exemestane 25 mg daily | SD | 12 |
4th | 2001/2 to 2001/6 | Lung | Epirubicin (75 mg/mq day1) and Docetaxel (80 mg/mq day1) w3a | SD | 4 |
5th | 2001/7 to 2002/1 | Lung | Letrozole (2.5 mg daily) and LHRHa | PD | 6 |
6th | 2002/2 to 2002/12 | Lung | Vinorelbine 25 mg/m2 IV day 1–>5 w3 | PD | 10 |
7th | 2002/12 to 2007/10 | Lung | Megestrol 160 mg dailyb | PR | 58 |
8th | 2007/10 to 2008/5 | Lung | Tamoxifen 20 mg daily | PR | 7 |
2008/6 to 2009/1 | No therapy | ||||
9th | 2009/1 to 2011/2 | Lung | Capecitabine 1000 mg/mq b.i.d. from days 1 to 14, w3 | SD | 25 |
10th | 2011/2 to 2013/3 | Lung | Cyclophosphamide 50 mg/die PO and Methotrexate 2, 5 mg PO twice a week | SD | 25 |
2013/4 | Lung, bone | Palliative radiant treatment for bone metastases of sacral spine. | |||
11th | 2013/5 to 2013/10 | Lung, bone, nodes | Carboplatinum (AUC5) w3, Zoledronic acid | PD | 5 |
12th | 2013/10 to 2014/4 | Lung, bone, nodes, subcutaneous | Eribuline 1.2 mg/m2 day 1–8 w3c Zoledronic Acid | PD | 6 |
13th | 2014/5 to 2014/9 | Lung, bone, nodes, subcutaneous | Everolimus 10 (5) mg daily and Exemestane 25 mg dailyd | PR | 4 |